Definium Therapeutics, Inc. (DFTX) — SEC Filings
Definium Therapeutics, Inc. (DFTX) — 36 SEC filings. Latest: 4 (Mar 26, 2026). Includes 20 8-K, 5 10-Q, 4 SC 13G.
View Definium Therapeutics, Inc. on SEC EDGAR
Overview
Definium Therapeutics, Inc. (DFTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Mar 26, 2026: On March 25, 2026, Mark Sullivan, a reporting person for Definium Therapeutics, Inc., reported a change in beneficial ownership of securities. The filing details transactions related to the company's stock, but specific details on the nature of the change or dollar amounts are not provided in this e
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 2 bearish, 34 neutral. The dominant filing sentiment for Definium Therapeutics, Inc. is neutral.
Filing Type Overview
Definium Therapeutics, Inc. (DFTX) has filed 1 4, 1 144, 5 10-Q, 20 8-K, 2 DEF 14A, 2 10-K, 1 SC 13G/A, 4 SC 13G with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of DFTX's 29 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$133.36M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $19.96M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Mark Sullivan
- Carol A. Vallone
- Andreas Krebs
- Dr. Suzanne Bruhn
- Dr. Roger Crystal
- David Gryska
- Robert Barrow
Industry Context
The psychedelic-assisted therapy sector is rapidly evolving, with companies like MindMed focused on developing novel treatments for mental health conditions. The competitive landscape includes other biotech firms pursuing similar therapeutic avenues, as well as traditional pharmaceutical companies exploring new drug candidates. Regulatory pathways for these novel therapies are still being defined, creating both opportunity and uncertainty.
Top Tags
filing (7) · financials (6) · material-agreement (4) · 8-k (4) · corporate-governance (4) · 10-Q (4) · regulatory-filing (3) · equity-sale (3) · corporate-filing (3) · biotech (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $133.36M | Increased from $73.94M in 2024, indicating higher operating costs. |
| Research and Development Expenses | $84.14M | Increased 93.3% from $43.54M in 2024, reflecting intensified clinical trials. |
| Cash and Cash Equivalents | $19.96M | Decreased 92.7% from $273.74M at Dec 31, 2024, signaling rapid cash burn. |
| Accumulated Deficit | $532.24M | Increased from $398.88M at Dec 31, 2024, highlighting ongoing losses. |
| Change in Fair Value of 2022 USD Financing Warrants | $17.77M | Expense for 9 months ended Sep 30, 2025, impacting net loss. |
| Credit Facility, Long-term | $40.39M | Increased from $21.85M at Dec 31, 2024, indicating increased debt financing. |
| Common Shares Outstanding | 98,509,279 | As of October 31, 2025, indicating potential dilution. |
| Commission File Number | 001-40360 | Identifier for MindMed's SEC filings |
| IRS Employer Identification No. | 98-1582438 | Tax identification for MindMed |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the fiscal quarter for this filing. |
| Filing Date | 2025-05-08 | The date the 10-Q was officially submitted to the SEC. |
| SEC File Number | 001-40360 | Identifies the company's filings with the SEC. |
| Film Number | 25861688 | Internal SEC processing number for the filing. |
| Fiscal Year End | 2024 | The period covered by the 10-K filing. |
| Business Phone | 212-220-6633 | Contact number for the company. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Definium Therapeutics, Inc. (DFTX)?
Definium Therapeutics, Inc. has 36 recent SEC filings from Jan 2024 to Mar 2026, including 20 8-K, 5 10-Q, 4 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DFTX filings?
Across 36 filings, the sentiment breakdown is: 2 bearish, 34 neutral. The dominant sentiment is neutral.
Where can I find Definium Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Definium Therapeutics, Inc. (DFTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Definium Therapeutics, Inc.?
Key financial highlights from Definium Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DFTX?
The investment thesis for DFTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Definium Therapeutics, Inc.?
Key executives identified across Definium Therapeutics, Inc.'s filings include Mark Sullivan, Carol A. Vallone, Andreas Krebs, Dr. Suzanne Bruhn, Dr. Roger Crystal and 2 others.
What are the main risk factors for Definium Therapeutics, Inc. stock?
Of DFTX's 29 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Definium Therapeutics, Inc.?
Forward guidance and predictions for Definium Therapeutics, Inc. are extracted from SEC filings as they are enriched.